At the end of 2018, Unisbi Pharmaceuticals' innovative drug for the treatment of Parkinson's disease, Eupro (Rotigotine Patch), was approved by the China Food and Drug Administration for marketing in China. As the first patch to treat Parkinson's disease, Uplow also gave Parkinson's patients a new choice of medication. A year has passed, what about this Parkinson's disease drug?
Introduction to Eupro (Rotigotine Patch).
Uprol, also known as rotigotine patch, is a unique dosage form and is the only transdermal patch in the world to treat Parkinson's disease, providing 24 hours of sustained and stable drug release. Rotigotine (generic name for the drug) is a dopamine receptor agonist, and is the same as Tessuda, Senforol, and Ropinirole, which are "stand-ins" for dopamine, acting in place of the missing dopamine in the human brain. The greatest contribution of this type of drug is that it can be combined with levodopa drugs (medopa, shinin, etc.), which greatly reduces the dose of levodopa and reduces the harm of sports complications.
As a transdermal patch, Upro is mainly applied to the clean, dry, intact and healthy skin surface of the abdomen, thighs, buttocks, flanks, shoulders or upper arms. For Parkinson's disease symptoms, Upro can be monotherapy for the signs and symptoms of early idiopathic Parkinson's disease, or in combination with levodopa, at various stages of the parkinson's disease course until the efficacy of L-Dopa in the advanced stages of the disease is diminished, unstable, or when Parkinson's symptoms fluctuate.
It can effectively improve the motor symptoms of Parkinson's patients, early Parkinson's disease can reduce the occurrence of sports complications, and patients with intermediate and advanced Parkinson's disease combined with levodopa can effectively reduce the off-time time. Due to the continuous and stable absorption of Upro, it can be used in patients with Parkinson's disease with sleep disorders, which can effectively improve symptoms such as sleep disorders and morning limb stiffness.
However, in the process of use of Parkinson's patients, it is necessary to pay attention to:
1. New patches need to be replaced every 24 hours
2. Avoid direct heating of the patch and lead to excessive drug release
3. When doing MRI or cardiac electroshock rescue, the patch must be removed first
4. The patch cannot be cut
5. After sticking, be sure to wash your hands
6. When replacing the patch, please fold the pasting of the old patch
7. Do not repeat the medication in the same part within 14 days
8. After the first use of the patch, it may take effect after 2 hours; if the patch is used regularly every day, the lag effect is not obvious
9. If the skin allergic reaction after the drug is severe, or even spreads to the outside of the drug site, please contact the doctor
10. Do not add patches at will and at any time. If you have serious reactions such as vomiting, confusion, hypotension, and convulsions after taking the drug, please go to the hospital emergency department as soon as possible
As a topical long-acting dopamine receptor agonist, oral dopa receptor agonists have some side effects like Upuro patches, and some Parkinson's patients say that the patch avoids nausea and vomiting caused by oral agonists, which is actually a wrong statement, and the patch has a gastrointestinal reaction. Dopaminergic adverse reactions may occur at the beginning of treatment, mainly nausea and vomiting. These reactions are usually mild or moderate and transient when treatment is continued, and data show that more than 10% of patients experience adverse reactions of nausea, vomiting, dosing site reactions, drowsiness, dizziness, and headache.
In general, as a new drug for the treatment of Parkinson's disease, the domestic listing of Upro (Rotigotine patch) can allow Parkinson's patients to have more drug choices, which has to be said to be a big step forward!